Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649910 | 1.00 | ACACB (0.60) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL648245 | 0.95 | ACACB (0.53) | ACACBMTNR1AMTNR1BNQO2KDM4E | |
| SCHEMBL648246 | 0.95 | ACACB (0.53) | ACACBMTNR1AMTNR1BNQO2KDM4E | |
| SCHEMBL649232 | 0.93 | ACACB (0.51) | ACACBMTNR1AMTNR1B | |
| SCHEMBL649231 | 0.93 | ACACB (0.51) | ACACBMTNR1AMTNR1B | |
| SCHEMBL650375 | 0.92 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL650374 | 0.92 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL648433 | 0.91 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL648434 | 0.91 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL647847 | 0.91 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119687-B2 | Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2012-02-21 | — | — | US | claimed |
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | claimed |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | claimed |
| EP-1537096-B1 | DERIVATIVES OF DIOXANE-2-ALKYL CARBAMATES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | EP | claimed |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-11-02 | — | — | US | claimed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | claimed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | claimed |
| US-20040224019-A1 | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs | SALVONA-IP LLC | 2004-11-11 | — | — | US | claimed |
| US-20210007990-A1 | COMPOSITIONS FOR STABILIZING AND DELIVERING PROTEINS | THERAPYX, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-2561854-B1 | Particles that disrupt or impede bacterial adhesion, related compositions and methods | COLGATE PALMOLIVE CO (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-1948124-B1 | PARTICLES THAT INHIBIT OR REDUCE BACTERIAL ADHESION ON AN ORAL SURFACE, RELATED COMPOSITIONS AND METHODS | COLGATE PALMOLIVE CO (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-1423175-B1 | METHODS FOR MICRONIZATION OF HYDROPHOBIC DRUGS | UNIV BROWN RES FOUND (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2561854-A1 | Particles that disrupt or impede bacterial adhesion, related compositions and methods | Colgate-Palmolive Company (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8211452-B2 | Particles that disrupt or impede bacterial adhesion, related compositions and methods | COLGATE-PALMOLIVE COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| US-6248720-B1 | NONINVASIVE DRUG DELIVERY OF BIOADHESIVE, MICROENCAPSULATED MICROPARTICLES CONTAINING A GENE UNDER THE CONTROL OF A PROMOTER TO A MUCOSAL EPITHELIAL SURFACE | BROWN UNIVERSITY RESEARCH FOUNDATION | 2001-06-19 | — | — | US | disclosed |
| US-6235224-B1 | DISSOLVING POLYMER IN SOLVENT, DISSOLVING OR DISPERSING AGENT TO BE ENCAPSULATED IN SAID SOLVENT, INTRODUCING MIXTURE INTO NONSOLVENT TO CAUSE SPONTANEOUS FORMATION OF MICROENCAPSULATED PRODUCT | BROWN UNIVERSITY RESEARCH FOUNDATION | 2001-05-22 | — | — | US | disclosed |
| US-6143211-A | FORMING A MIXTURE OF A POLYMER AND A SOLVENT, WHEREIN THE SOLVENT IS PRESENT IN A CONTINUOUS PHASE AND INTRODUCING THE MIXTURE INTO AN EFFECTIVE AMOUNT OF A NONSOLVENT TO CAUSE THE SPONTANEOUS FORMATION OF MICROPARTICLES | BROWN UNIVERSITY FOUNDATION (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0844871-A4 | A PROCESS FOR PREPARING MICROPARTICLES THROUGH PHASE INVERSION PHENOMENA | UNIV BROWN RES FOUND (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0844871-A1 | A PROCESS FOR PREPARING MICROPARTICLES THROUGH PHASE INVERSION PHENOMENA | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997003657-A1 | A PROCESS FOR PREPARING MICROPARTICLES THROUGH PHASE INVERSION PHENOMENA | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | CHRM3, CHRM2, CHRM4 | ACACB 681/4885MTNR1A 540/4885MTNR1B 1234/4885 |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.